iBio, Inc.
About iBio, Inc.
At iBio, we’re pioneering the next generation of biopharmaceuticals using the FastPharming System, our proprietary plant-based recombinant protein manufacturing platform. The speed, safety and scalability inherent in the FastPharming Technology makes it ideal for rapidly advancing promising candidates from concept to clinic, while also enabling “greener” manufacturing. We seek to change the paradigm of drug development by reducing the time, costs, and scale-up issues associated with traditional mammalian cell culture production – thus making plant-based manufacturing the preferred choice for high quality biopharmaceutical development.
Stock Symbol: IBIO
132 articles with iBio, Inc.
-
Some might go as far as to consider the pharmaceutical industry as mankind’s best hope for survival. But now, as the world enters the third year of the pandemic, has that perception changed?
-
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
8/25/2021
RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research, development, and commercialization of epitope-targeted antibody therapeutics.
-
Thinking about buying stock in Ion Geophysical, Moneygram International, Akebia Therapeutics, iBio, or Exela Technologies?
7/16/2021
InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA.
-
Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.
-
iBio, Inc. Enters Into Common Stock Purchase Agreement For Up To $16.0 Million With Lincoln Park Capital
7/24/2017
-
iBio, Inc. Provides Corporate Update At Annual Shareholders Meeting
5/5/2017
-
Another iBio, Inc. Plague Vaccine Patent Issues
11/22/2016
-
iBio, Inc. Expands Product Development Capacity Of cGMP Plant
11/15/2016
-
iBio, Inc. Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development For South African Biotech Company AzarGen Biotechnologies (Pty) Ltd
9/29/2016
-
Implications Of Court Decision In Favor Of iBio, Inc. Against Fraunhofer
8/17/2016
-
iBio, Inc.'s Claims Against Fraunhofer Affirmed By Delaware Chancery Court
8/5/2016
-
iBio, Inc. Receives FDA Orphan Drug Designation For Fibrosis Product Candidate
7/5/2016
-
iBio, Inc. Receives New Patent For Its Biotherapeutic Products For Treatment Of Fibrosis
6/30/2016
-
Texas A&M University System And iBio, Inc. Execute Joint Development Agreement For Plant-Produced Pharmaceuticals
6/7/2016
-
iBio, Inc. Holds Annual Meeting In College Station, Texas
4/11/2016
-
iBio, Inc. Unveils First Of Its Kind Patient Center Empowering Patients To Positively Impact The Future Of Research
2/12/2016
-
iBio, Inc. Forms Joint Venture CMO For Large-Scale Pharmaceuticals Manufacturing In Green Plants And Accepts Additional Investment
1/14/2016
-
iBio, Inc. Continues Global Expansion Of Intellectual Property
12/1/2015
-
iBio, Inc. Release: Scientific Insights Into IBIO-CFB03 Presented At American College of Rheumatology Annual Meeting
11/20/2015